The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Duration of the anti-androgen in men undergoing six months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
 
Nina Niu Sanford
No Relationships to Disclose
 
Ming-Hui Chen
No Relationships to Disclose
 
Marian J. Loffredo
No Relationships to Disclose
 
Andrew A. Renshaw
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Blend Therapeutics; Metamark Genetics; Placon
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Cristal Therapeutics; Endocyte; Genentech/Roche; GTx; Ipsen; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Pfizer; Sanofi; Sotio; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Sanofi
 
Anthony Victor D'Amico
No Relationships to Disclose